Physician profile
Aditi Kumar
NPI 1497061915
$5,336.14
in general payments reported to CMS, 2019-2025
27 companies · $2,452 in 2025
The $2,452 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,977 · 2020: $143 · 2021: $600 · 2024: $165 · 2025: $2,452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,293 · Food and Beverage: $309 · Education: $14.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,292.50 |
| Food and Beverage | $309.15 |
| Education | $14.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $2,417.44 | 2025 | Korlym |
| Medtronic Minimed, INC. | $1,214.41 | 2019 | |
| Novo Nordisk INC | $249.98 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $237.72 | 2019-2021 | |
| Mannkind Corporation | $186.59 | 2019 | |
| Samsung Hme America, INC. | $150.00 | 2024 | |
| Pharmacosmos Therapeutics INC. | $122.82 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $77.01 | 2019-2021 | |
| Lilly USA, LLC | $65.08 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $64.20 | 2019-2021 | |
| Abbott Laboratories | $61.64 | 2019-2021 | |
| Amgen INC. | $55.69 | 2019-2020 | |
| Insulet Corporation | $49.75 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $49.00 | 2019 | |
| Radius Health, INC. | $46.09 | 2021-2024 | Tymlos |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $43.92 | 2021 | |
| Shire North American Group INC | $38.25 | 2019 | |
| Recordati_rare_diseases_inc. | $34.21 | 2025 | Isturisa |
| Bayer Healthcare Pharmaceuticals INC. | $32.89 | 2021 | |
| Abbvie INC. | $32.32 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $19.03 | 2021 | |
| Ferring Pharmaceuticals INC. | $18.19 | 2019 | |
| Tandem Diabetes Care, INC. | $17.61 | 2019 | |
| Merck Sharp & Dohme LLC | $15.12 | 2019 | |
| Antares Pharma, INC. | $14.64 | 2019 | |
| Vistapharm, INC. | $13.03 | 2021 | |
| Vivus LLC | $9.51 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aditi Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.